Mr. Bill Mitoulas reports

MEDX HEALTH CORP. ANNOUNCES PROPOSED EXTENSION OF NON-BROKERED PRIVATE PLACEMENT OFFERING

Subject to acceptance by the TSX Venture Exchange, the ultimate closing date for MedX Health Corp.'s non-brokered private placement of up to $1.5-million, which was previously announced on Aug. 30, 2023, will be extended by up to 30 days. The company has already received conditional acceptance for the placement from the TSX-V, but closing for the full amount of the proposed placement has been delayed. The proposed placement, to accredited investors, is for the placement of up to 21,428,571 units at seven cents per unit. Each unit will comprise one fully paid common share and one share purchase warrant, exercisable to purchase one further common share at the price of 12 cents, exercisable for a period commencing on the date of issue and expiring on Dec. 31, 2026. Closing of the placement, which may take place in tranches, will be subject to receipt of subscriptions for a minimum of $500,000 and a number of other conditions, including, without limitation, the receipt of all relevant regulatory and stock exchange approvals or acceptances. Qualified agents may receive commissions in respect of subscriptions introduced by them by way of cash equal to 6 per cent of funds so introduced and issuance of agents' warrants equal in number to 6 per cent of the number of units so subscribed for. Each agent's warrant, which is non-transferable, will be exercisable to acquire one unit at seven cents per unit, at any time during the period of two years following the closing.

About MedX Health Corp.

MedX, headquartered in Ontario, Canada, is a leading medical device and software company focused on skin health with its SIAscopy on DermSecure telemedicine platform, utilizing its SIAscopy technology. SIAscopy is also imbedded in its products, SIAmetrics, SIMsys and MoleMate, which MedX manufactures in its ISO 13485-certified facility. SIAmetrics, SIMsys and MoleMate include hand-held devices that use patented technology utilizing light and its remittance to view up to two millimetres beneath suspicious moles and lesions in a pain-free, non-invasive manner, with its software then creating real-time images for physicians and dermatologists to evaluate all types of moles or lesions within seconds. These products are cleared by Health Canada, the U.S. Food and Drug Administration, the Therapeutic Goods Administration, and Conformite Europeenne for use in Canada, the United States, Australia, New Zealand, the European Union, Brazil and Turkey.

We seek Safe Harbor.